Associate Principal Scientist AstraZeneca Mölndal, Vastra Gotaland, Sweden
Abstract: SLAS Europe 2024 Conference and Exhibition Martin Svensson, Silvio Di Castro, Compound Synthesis & Management, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden
In recent years, pharmaceutical research has increased its focus towards novel drug modalities other than small molecules, in a bid to overcome limitations of classical therapeutic approaches, and find new and more effective ways to cure diseases.
To support so-called "new modalities", Compound Management teams around the globe are working to adapt their processes, workflows and equipment in order to successfully handle them with the same quality and speed that has been applied to small molecule research projects for decades.
Here we share our approach in supporting next generation therapeutics through the introduction of hardware and software solutions that support versatile multi-solvent workflows in the high-throughput setting of Compound Management at AstraZeneca, from library submission to assay-ready plate generation, the challenges we have faced so far and any associated process improvements that have been introduced along the way.
Working with our business partners, we are setting up solid foundations for the future of our research and bring new efficacious drugs into the clinics, as well as establishing new best practices that will be developed in the years to come.
